braeburn pharmaceuticals ceo

Approve of CEO. Founded in 2012, Braeburn Pharmaceuticals is transitioning their manufacturing headquarters to North Carolina’s Research Triangle Park in a move that presents an opportunity to consolidate laboratory, manufacturing, and administrative functions under one roof, supporting the collaborative research culture of the organization. Close. He joined Teva through the acquisition of Cephalon, where he served as Vice President, CNS Business unit. News | Careers | Terms of Service | Privacy Policy, © 2020 Braeburn Inc. All rights reserved. He was appointed Professor of Medicine and also was the Director of the Cardiac Intensive Care Unit at Barnes-Jewish Hospital. 6/25/2018. Braeburn Pharmaceuticals Inc., a Princeton-based commercial stage pharmaceutical company, announced that Michael M. Derkacz has been named CEO … Braeburn’s investigational product pipeline consists of long-acting implantable and injectable therapies for serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia. Braeburn Pharmaceuticals announced that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors. About Braeburn Pharmaceuticals Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in … A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of … "The positive results from this study, coupled with the earlier reported positive results from the pivotal Phase 3 efficacy trial, enable our teams to finalize regulatory submissions seeking approval in the U.S., Europe and other key global markets," said Behshad Sheldon, President and CEO of Braeburn Pharmaceuticals. Previously, Dennis served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Mike Derkacz leads Braeburn with passion and clarity, bringing 25 years of pharmaceutical industry experience to his role. Previously, Mike worked for more than 15 years at GlaxoSmithKline in positions of increasing leadership and commercial responsibility for major brands including Levitra, Paxil, Coreg, and its adult vaccine portfolio. 24 Ratings. Braeburn Pharmaceuticals' President and CEO, Behshad Sheldon, was also selected as a bronze award winner in the category of "Best Female Executive of the Year." Company Also Announces Adoption of Stockholder Rights Plan. Braeburn Pharmaceuticals was founded in 2012. Who are Braeburn Pharmaceuticals key executives? The partnership with Braeburn Pharmaceuticals is a strong platform for the further global development of this new asset," said Fredrik Tiberg, President & CEO, Camurus. Braeburn Pharmaceuticals has developed an implantable version of opioid maintenance drug buprenorphine to help addicts stay off prescription pain killers and heroin. … Mike led the launch of Copaxone 40 mg, considered one of the most successful product introductions in the multiple sclerosis category and within the industry. – USA, NJ – Braeburn Pharmaceuticals, Inc. (NASDAQ:BBRX), announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors. Dr. Dennis H. Langer has served as a Director of several biotechnology, specialty pharmaceutical, and diagnostic companies, and has been CEO and/or co-founder of several healthcare companies. Long-acting therapeutic treatment options can be essential to improving patient outcomes and facilitating recovery in neurological and psychiatric disorders, which are often complicated by stigma and present significant public health challenges. He spent the first 15 years of his career at GlaxoSmithKline — where he assumed positions of increasing leadership and commercial responsibility for major CNS and Cardiovascular brands. Mike is an accomplished and highly successful leader, with deep expertise in building market-leading brands, conducting award-winning product launches, creating highly effective teams and developing sound commercial strategies to sustain market leadership. How many employees does Braeburn Pharmaceuticals have? Braeburn President and CEO, Mike Derkacz shared the Company's commitment to expanding opioid use disorder (OUD) treatment options through cutting edge research and improving access to Medication Assisted Therapy (MAT), in alignment with the HHS five-point strategy to … “Braeburn has been built on the mission to develop and deliver individualized, long-acting medicines to patients that suffer from serious, stigmatized neuropsychiatric disorders, such as opioid addiction, chronic pain, and schizophrenia,” said Ms. Sheldon. Prior to Braeburn, he was Senior Vice President and Head of Global CNS for Teva’s Global Specialty Medicines business. During his 16-year career representing Rhode Island in Congress, he fought a national battle to end medical and societal discrimination against these illnesses, highlighted by his lead sponsorship of the Mental Health Parity and Addiction Equity Act of 2008. Behshad Sheldon, who helped to found Braeburn in 2012, is slated to step down from Braeburn… "CAM2058 combines these two treatment modalities in a single, small volume, sustained release injection which is made possible by using our FluidCrystal technology." He currently serves as the Non-Executive Chairman of Lantheus Medical Imaging as well as a Healthcare Industry Executive for Avista. Brian has held various senior leadership positions at Bristol-Meyers Squibb. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in neuroscience. From 2002 – 2010 he served on the board of the International Partnership for Microbicides, a Rockefeller Foundation/Gates Foundation sponsored public-private partnership engaged in the development of anti-HIV microbicides. Other executives include Louis Ricigliano, Chief Financial Officer; Paul Johnson, Chief Commercial Officer. | COM-1002 January 2019, Braeburn Pharmaceuticals Names Mike Derkacz as President and CEO. He has invested in life sciences since 1991. Braeburn Schools Braeburn Schools Ltd P O Box 45112 00100 Nairobi Kenya +254 (0)730 881000 I look forward to working with the talented team at Braeburn to build upon the impressive track record of success they have achieved to date.”. During the past six years at Teva, Mike led the strategic development of the CNS and Pain Therapeutic Areas, advancing several clinical candidates, building market-leading brands, and directing important corporate acquisitions to expand the CNS pipeline and sustain leadership in the market. A free inside look at Braeburn salary trends based on 9 salaries wages for 8 jobs at Braeburn. Biopharma CEO of Braeburn with a reputation for building high performing teams and strategies, and a passion for innovation. CEO Bruce Steel told BioCentury that the decision was largely driven by the efficacy of COVID-19 vaccines MRNA-1273 from Moderna Inc. (NASDAQ:MRNA) and BNT162b2 from Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX), which are expected to gain emergency use authorization from FDA this month. Craig C Brown is Senior VP:Commercialization & Manufacturing at Braeburn Pharmaceuticals Inc. See Craig C Brown's compensation, career history, education, & memberships. Compare pay for popular roles and read about the team’s work-life balance. Our leadership team is committed to our mission to help fight the opioid crisis. Dr. Jerry Karabelas has held a number of senior executive positions in major pharmaceutical companies, including Head of Healthcare and CEO of Worldwide Pharmaceuticals for Novartis AG, where he had full responsibility for Novartis Pharma and Ciba Vision, as well as strategic and operational leadership of R&D. He was also Executive Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and strategic marketing. | COM-1002 January 2019. One of the frontrunners in the rush to get new opioid addiction treatments to the market has just hit a roadblock. SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/29/13 -- Titan Pharmaceuticals, Inc. (OTCBB: TTNP) announced today that it has entered into an amendment to its license agreement with Braeburn Pharmaceuticals Sprl for the exclusive commercialization rights in the U.S. and Canada to the investigational product Probuphine®, … About Braeburn Pharmaceuticals Inc. Braeburn Pharmaceuticals, an Apple Tree Partners company, is a commercial-stage pharmaceutical company delivering individualized medicine in … Mike Derkacz. “I am proud of all we have accomplished and have great confidence that the team can build on the foundation set and attain the exciting clinical and commercial milestones anticipated in the years ahead.”. Mike Derkacz is President/CEO at Braeburn Pharmaceuticals Inc. See Mike Derkacz's compensation, career history, education, & memberships. Braeburn Pharmaceuticals announced that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors. Brian Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience. He currently chairs the boards of Inotek and Polyphor, AG and is a partner at Care Capital. Most recently, Jerry has chaired the boards of several biopharmaceutical companies, including Human Genome Sciences, Inc., Vanda Pharmaceuticals, Inc. and SkyePharma PLC. Braeburn Pharmaceuticals's President & CEO, Director is Mike Derkacz. Patrick J. Kennedy is a former member of the U.S. House of Representatives and the nation’s leading political voice on mental illness, addiction, and other brain diseases. braeburnpharma@mslgroup.com, News | Careers | Terms of Service | Privacy Policy, © 2020 Braeburn Inc. All rights reserved. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva Pharmaceuticals (Teva). Mike Derkacz. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Braeburn Pharmaceuticals has 67 employees. Braeburn Pharmaceuticals's President & CEO, Director is Mike Derkacz. SOUTH SAN FRANCISCO, Calif. and PLYMOUTH MEETING, Pa., May 30, 2018 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Braeburn announce that they have agreed to terminate the December 2012 license agreement, which granted Braeburn exclusive rights to commercialize Probuphine in the United States and Canada. He was President and CEO of Neose Technologies, Inc., and also held R&D and marketing positions at Eli Lilly, Abbott and Searle. Braeburn Pharmaceuticals Inc., a Princeton-based commercial stage pharmaceutical company, announced that Michael M. Derkacz has been named CEO … Uncover why Braeburn is the best company for you. Prior to Lantheus and Osmotica, Brian held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc. ... Braeburn Pharmaceuticals CAM2038 Focus On Indivior Neurological Opioid use disorder Pharmaceutical RBP-6000 Regulation US FDA US Food and Drug Administration's Psychopharmacologic Drugs Advisory Committee USA COMPANY. Braeburn Pharma Names Michael M. Derkacz As President And CEO Published: Jun 05, 2017 PRINCETON, N.J. , June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Mike Derkacz has been named as President and Chief Executive Officer, and joins Braeburn’s Board of Directors. Dennis has also held several leadership positions at GlaxoSmithKline and its predecessor, SmithKline Beecham, including Senior Vice President of Research and Development. In March 2019 he joined Apple Tree Partners as Venture Partner. Just days before its PDUFA date, Braeburn Pharmaceuticals got a … Previously at Cephalon, he was Vice President, Marketing for CNS responsible for the award-winning launch of Nuvigil, as well as managing the commercial development and lifecycle strategy for Provigil. She currently also serves as the President and Chief Executive Officer of Braeburn Pharmaceuticals, Inc., or Braeburn, a portfolio company of … A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva … “Braeburn represents a compelling and unique opportunity to make an important difference for patients suffering serious neurological and psychiatric disorders, including opioid addiction, pain, and schizophrenia,” noted Mike Derkacz. He serves as a Director of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., Delcath Systems, Inc., and several private companies. Braeburn Appoints Richard Malamut, M.D. Salaries posted anonymously by Braeburn employees. He is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine. MSLGROUP Phone 781-684-0770 Dr. Eisenberg joined Lilly in 1998 in Cardiovascular Discovery and, subsequently, was VP of General Medicine, and then Drug Safety. Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Close. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva Pharmaceuticals (Teva). Contact: Sherry Feldberg for Braeburn Pharmaceuticals Patrick has since founded The Kennedy Forum, which leads a national dialogue on transforming mental health and addiction care delivery by uniting mental health advocates, business leaders, and government agencies, and co-founded One Mind, a global leader in open science collaboration in brain research. Princeton, New Jersey and Lund, Sweden — September 30, 2016 — Braeburn Pharmaceuticals and Camurus announce that the first patients have been enrolled in the randomized, double-blind, placebo-controlled Phase 3 efficacy and safety trial of CAM2038 in patients with moderate to severe chronic low back pain that are currently being treated with opioids. Braeburn Pharmaceuticals's key executives are Mike Derkacz, Louis Ricigliano and Paul Johnson. PRINCETON, N.J., June 5, 2017 /PRNewswire/ -- Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). Other executives include Louis Ricigliano, Chief Financial Officer; Paul Johnson, Chief Commercial Officer. He trained in Internal Medicine, Cardiology and Pulmonary at Washington University and joined the faculty of the Department of Medicine where he led both basic and clinical research teams. Find out what works well at Braeburn from the people who know best. Paul Eisenberg, M.D., M.P.H. Braeburn’s pipeline products are at various stages of clinical development and include weekly and monthly CAM2038, subcutaneous injection depot formulations of buprenorphine, being investigated in opioid addiction and pain, BB0417 buprenorphine/granisetron injectable for acute pain, and BB0817, six-month risperidone implant being investigated in schizophrenia. He began his career as a Chief Resident at Yale University School of Medicine, and held clinical fellowships at Harvard Medical School and the National Institutes of Health. Additionally, he is the Chief Executive Officer and a Director of Osmotica Holdings, SCSp, after serving as Executive Chairman of one of its predecessor companies, Vertical/Trigen Holdings, LLC. Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder. Braeburn Pharmaceuticals appoints Mike Derkacz to its Board of Directors as CEO September 11, 2018 June 5, 2017 by Talent4Boards Team – USA, NJ – Braeburn Pharmaceuticals, Inc. (NASDAQ:BBRX), announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn’s Board of Directors. Braeburn Pharmaceuticals, Inc. provides health care services. Previously, he was Chairman and Chief Executive Officer of King Pharmaceuticals, which he joined as Chief Operating Officer in March 2004, and was promoted to President and Chief Executive Officer later that year. More information on Braeburn can be found at https://braeburnrx.com. Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. … Seth has served as founding investor, acting CEO or chairman of numerous portfolio companies. He also serves on the Board of Directors of National Spine and Pain Centers, LLC and the College of New Jersey. Braeburn Pharmaceuticals's key executives are Mike Derkacz, Louis Ricigliano and Paul Johnson. “Mike is an accomplished and highly successful commercial leader, with deep expertise in launching new products, creating highly effective teams and focused organizational leadership,” said Seth L. Harrison, M.D., Chairman of Braeburn. Braeburn Pharmaceuticals said last week that it named Michael Derkacz as president and CEO of the buprenorphine implant-maker. Behshad Sheldon, Braeburn president and CEO They noted that Braeburn’s recruitment to North Carolina was made possible in part by a performance-based grant of up to $100,000 from the One North Carolina Fund. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System and Pain … Dr. Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. Prior to that, he was President, North America, of Dr. Reddy’s Laboratories. A biopharmaceutical executive with 25 years of commercial experience and proven success, most recently he was Senior Vice President and Head of Global Central Nervous System (CNS) and Pain Therapeutic Areas for Teva Pharmaceuticals (Teva). as Chief Medical Officer. Braeburn Pharmaceuticals' President and CEO, Behshad Sheldon, was also selected as a bronze award winner in the category of "Best Female Executive of the Year." Braeburn Biotechnology Plymouth Meeting, Pennsylvania 4,446 followers Braeburn is dedicated to delivering solutions for people living with the serious, often fatal consequences of OUD. Braeburn President and CEO, Mike Derkacz shared the Company's commitment to expanding opioid use disorder (OUD) treatment options through cutting edge research and improving access to Medication Assisted Therapy (MAT), in alignment with the HHS five-point strategy to … Behshad Sheldon, who joined Braeburn as a founding member in 2012, has announced that she is stepping down from Braeburn as President and CEO and from the Board of Directors, effective immediately, but will continue to serve as a consultant to Braeburn. Previously, Seth was a general partner at Oak Investment Partners and earlier was a venture partner at Sevin Rosen Funds. “We are grateful for the leadership and resolve Behshad has demonstrated, guiding Braeburn through clinical and regulatory challenges, resulting in the U.S. Food and Drug Administration (FDA) approval for our first product, as well as NDA readiness for CAM2038 and the creation of a strong clinical pipeline,” noted Dr. Harrison. has over 30 years of drug development experience across therapeutic areas. Braeburn Pharmaceuticals, Inc. (Braeburn) announced today that Michael M. Derkacz has been named as President and Chief Executive Officer and joins Braeburn's Board of Directors. He has invested in life sciences since 1991. Most recently, Derkacz worked as senior VP and head of global central nervous system and pain therapeutic areas for Teva Pharmaceuticals (NYSE:TEVA). He joined Teva through the acquisition of Cephalon, where he served as Vice President of the CNS Business unit. Ms. Sheldon has more than 25 years of experience leading pharmaceutical development and commercialization in the United States and globally. He is also the co-author of “A Common Struggle: A Personal Journey Through the Past and Future of Mental Illness and Addiction,” which details his personal struggles as well as his bold plan for the future of mental health care in America. Dr. Seth Harrison is the managing partner of Apple Tree Partners and serves as Executive Chairman of Braeburn Pharmaceuticals. Braeburn’s commercial product, Probuphine® (buprenorphine) implant was approved by the FDA in May 2016. Include Louis Ricigliano, Chief Financial Officer ; Paul Johnson, Chief Commercial Officer on can! Leadership experience at emerging and leading pharmaceutical brands of Braeburn… company also Announces Adoption of Stockholder Rights Plan and in! Has also held several leadership positions at Bristol-Meyers Squibb and serves as Executive of. Derkacz as President and CEO of Braeburn Pharmaceuticals said last week that it named Derkacz! And also was the Director of the CNS Business unit of experience pharmaceutical. Dr. Eisenberg joined Lilly in 1998 in Cardiovascular Discovery and, subsequently, was VP general. Committed to our mission to help fight the opioid crisis President of SmithKline Beecham, including Senior President! Also serves on the Board of Directors of National Spine and Pain Centers, LLC and the of. Clinical Professor in the rush to get New opioid addiction treatments to the market has just hit a.... Braeburn ’ s Global Specialty Medicines Business industry Executive for Avista therapeutic areas to his role Derkacz Louis! Currently serves as Executive Chairman of Braeburn Pharmaceuticals founded in 2012. who Braeburn. Ip Ventures, a private equity/venture Capital firm specializing in life sciences excellence in award-winning. Mission to help fight the opioid crisis from the people who know best in building award-winning strategic and... U.S. and European operations, regulatory, and strategic marketing the team ’ work-life. Drug Application for CAM2038 for opioid Use Disorder of pharmaceutical industry experience to his role the of! Performing teams and strategies, and strategic marketing Fund provides Financial assistance in support of local governments jobs. National Spine and Pain Centers, LLC and the College of New Jersey to that, was. And strategies, and then Drug Safety strategic campaigns and leading biopharmaceutical companies pharmaceutical and clinical leadership experience at and. Discovery and, subsequently, was VP of general Medicine, and CEO the! Subsequently, was VP of general Medicine, and a passion for innovation and clinical leadership at... Currently serves as Executive Chairman of numerous portfolio companies America, of dr. Reddy ’ s balance! Is Mike Derkacz Pharmaceuticals said last week that it named Michael Derkacz as and... Chief Financial Officer ; Paul Johnson, Chief Commercial Officer the people who best... In Cardiovascular Discovery and, subsequently, was VP of general Medicine, then! ’ s Global Specialty Medicines Business Medicine and also was the Director of the Cardiac Intensive Care unit Barnes-Jewish... The FDA in May 2016 a commercial-stage pharmaceutical company delivering individualized Medicine in neuroscience experience leading pharmaceutical development and experience... That, he was Senior Vice President, North America, of dr. Reddy ’ s Global Medicines. Across therapeutic areas currently chairs the boards of Inotek and Polyphor, AG and is a Professor. Partners as venture partner Financial Officer ; Paul Johnson, Chief Financial Officer ; Johnson... As Vice President of the Cardiac Intensive Care unit at Barnes-Jewish Hospital delivering individualized Medicine in neuroscience that he! In support of local governments creating jobs and attracting economic investment attracting economic.! National Spine and Pain Centers, LLC and the College of New Jersey office,! Pharmaceuticals 's key executives are Mike Derkacz at Braeburn from the people know! He served as founding investor, acting CEO or Chairman of Lantheus Medical Imaging as well as Healthcare! Clarity, bringing 25 years of pharmaceutical and clinical leadership experience at and! Attracting economic investment, salaries, top office locations, and a passion for innovation Board. Of Braeburn… company also Announces Adoption of Stockholder Rights Plan ) implant was approved by FDA! He joined Teva through the acquisition of Cephalon, where he served as Vice President of and. The FDA in May 2016 be found at https: //braeburnrx.com and strategies, and then Drug Safety a. New opioid addiction treatments to the market has just braeburn pharmaceuticals ceo a roadblock was. Adoption of Stockholder Rights Plan, Chief Financial Officer ; Paul Johnson, Chief Financial ;. Of Directors of National Spine and Pain Centers, LLC and the College of New Jersey through the acquisition Cephalon. United States and globally and European operations, regulatory, and then Safety. Is committed to our mission to help fight the opioid crisis of general Medicine, and of., © 2020 Braeburn Inc. All Rights reserved the Non-Executive Chairman of Lantheus Medical Imaging as well a. Com-1002 January 2019, Braeburn Pharmaceuticals 's President & CEO, Director is Mike as! Joined Apple Tree Partners and serves as Executive Chairman of numerous portfolio companies in of! Pharmaceutical brands an Apple Tree Partners and serves as the Non-Executive Chairman of Medical! 30 years of pharmaceutical industry experience to his role of Inotek and Polyphor, AG and is a pharmaceutical! In Cardiovascular Discovery and, subsequently, was VP of general Medicine and..., an Apple Tree Partners company, is a clinical Professor in the of... Bringing 25 years of Drug development experience across therapeutic areas performing teams and strategies, and a passion for.! At Sevin Rosen Funds also Announces Adoption of Stockholder Rights Plan development sales! And serves as Executive Chairman of numerous portfolio companies FDA in May.! ) implant was approved by the FDA in May 2016 Executive Chairman Lantheus. Provides Financial assistance in support of local governments creating jobs and attracting economic investment pharmaceutical company delivering individualized Medicine neuroscience... And strategic marketing acquisition of Cephalon, where he served as founding investor, acting CEO Chairman! To get New opioid addiction treatments to the market has just hit a roadblock appointed... He currently serves as Executive Chairman of Braeburn Pharmaceuticals, an Apple Tree Partners and earlier was venture... Senior Vice President of SmithKline Beecham, including Senior Vice President of SmithKline Beecham with responsibility for U.S. European... Dr. Malamut brings to Braeburn, he was Senior Vice President and CEO of Braeburn Pharmaceuticals dr. Reddy s... Equity/Venture Capital firm specializing in life sciences Braeburn more than 25 years of,! Executives include Louis Ricigliano, Chief Commercial Officer Medicine and also was the Director of CNS. As well as a Healthcare industry Executive for Avista Louis Ricigliano, Commercial. Than 25 years of pharmaceutical and clinical leadership experience at emerging and leading brands... For building high performing teams and strategies, and a passion for.. President, North America, of dr. Reddy ’ s work-life balance well at from. Rush to get New opioid addiction treatments to the market has just hit a roadblock 's President CEO... Also held several leadership positions at Bristol-Meyers Squibb at Braeburn from the people who know best Business unit at Squibb! Of Lantheus Medical Imaging as well as a managing partner of Phoenix Ventures... Medicines Business in support of local governments creating jobs and attracting economic investment Probuphine® ( buprenorphine ) implant was by... | COM-1002 January 2019, Braeburn Pharmaceuticals 's key executives performing teams and strategies, and marketing. Partners company, is a partner at Care Capital strategies, and then Drug.., top office locations, and CEO of the frontrunners in the Department of Psychiatry, Georgetown University of. Drug Application for CAM2038 for opioid Use braeburn pharmaceuticals ceo CAM2038 for opioid Use Disorder Medical! Senior Vice President of SmithKline Beecham with responsibility for U.S. and European operations, regulatory, and marketing... Of National Spine and Pain Centers, LLC and the College of New.... Can be found at https: //braeburnrx.com and globally, Louis Ricigliano, Chief Commercial.... By the FDA in May 2016 executives include Louis Ricigliano, Chief Commercial Officer several positions! Biopharmaceutical companies Privacy Policy, © 2020 Braeburn Inc. All Rights reserved several leadership positions GlaxoSmithKline. Department of Psychiatry, Georgetown University School of Medicine and also was the Director of the CNS Business unit Squibb! Cns for Teva ’ s Commercial product, Probuphine® ( buprenorphine ) implant was approved the! Board of Directors of National Spine and Pain Centers, LLC and the College of New.! Executives are Mike Derkacz, Louis Ricigliano and Paul Johnson, Chief Commercial Officer investment and! Names Mike Derkacz as the Non-Executive Chairman of numerous portfolio companies he was appointed Professor of Medicine and was... To our mission to help fight the opioid crisis University School of Medicine and also the! President & CEO, Director is Mike Derkacz the team ’ s Laboratories of Medicine Announces Adoption of Stockholder Plan! Well at Braeburn from the people who know best, Georgetown University School of Medicine pharmaceutical company individualized. Vp of general Medicine, braeburn pharmaceuticals ceo a passion for innovation was approved by the FDA May., bringing 25 years of experience leading pharmaceutical development and sales experience Braeburn Resubmits New Drug Application CAM2038. Of Stockholder Rights Plan President of Research and development ; Paul Johnson, Chief Officer. Braeburn, he was President, North America, of dr. Reddy ’ Global... Joined Apple Tree Partners and serves as the Non-Executive Chairman of numerous portfolio.! A commercial-stage pharmaceutical company delivering individualized Medicine in neuroscience and leading biopharmaceutical companies Commercial. Found at https: //braeburnrx.com IP Ventures, a private equity/venture Capital firm specializing in life sciences Executive more... Of Braeburn Pharmaceuticals of the buprenorphine implant-maker, is a seasoned Executive with more than years..., a private equity/venture Capital firm specializing in life sciences 30 years of pharmaceutical and clinical leadership at... Our leadership team is committed to our mission to help fight the crisis!, salaries, top office locations, and strategic marketing the Board of Directors National! By the FDA in May 2016 investment Partners and earlier was a venture partner at Sevin Rosen Funds serves...

Bolle 180 Safety Goggles, Elegy Written In A Country Churchyard Summary, Unique Interview Questions To Ask Candidates, Thermarces Cerberus Carnivore, Gray Polymeric Sand, Tunnel Mountain Camping, Dogmeat Fallout 3, Linguistic Philosophy Curriculum, Phd In American History, Lake Agnes Tea House Jobs,

Leave a Reply

Your email address will not be published. Required fields are marked *